All data are based on the daily closing price as of May 30, 2025
c

Chugai Pharmaceutical

4519.TSE
52.63 USD
0.27
+0.52%

Overview

Last close
52.63 usd
Market cap
86.61B usd
52 week high
59.92 usd
52 week low
29.51 usd
Target price
57.21 usd

Valuation

P/E
29.7139
Forward P/E
27.5482
Price/Sales
10.1258
Price/Book Value
6.5575
Enterprise Value
80.25B usd
EV/Revenue
9.4606
EV/EBITDA
19.9765

Key financials

Revenue TTM
8.48B usd
Gross Profit TTM
6.02B usd
EBITDA TTM
4.20B usd
Earnings per Share
1.76 usd
Dividend
0.68 usd
Total assets
14.35B usd
Net debt
-2.75B usd

About

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; and research collaboration and option to license agreement with Araris Biotech AG to develop ADCs using Araris AraLinQ technology. The company was founded in 1925 and is headquartered in Chuo-ku, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
  • Symbol
    4519.TSE
  • Exchange
    TSE
  • Isin
    JP3519400000
  • Country
    Japan
  • Sector
    Healthcare
  • Industry
    Drug Manufacturers - General
  • CEO
    Dr. Osamu Okuda
  • Headquarter
    Chuo
  • Web site
    https://www.chugai-pharm.co.jp
Jakota Newsletter

Stay ahead in the JAKOTA stock markets with our roundup of vital insights

Icon scroll to top